At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VOR Vor Biopharma Inc.
Trading 12-30 12:36:23 EST
12.82
-0.90
-6.56%
High13.65Low12.65Vol1.02M
Open13.61D1 Closing13.72Amplitude7.29%
Mkt Cap496.39MTradable Cap243.21MTotal Shares38.72M
T/O13.47MT/O Rate5.39%Tradable Shares18.97M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Vor Biopharma Adds Andrew Levin and Wouter Joustra to Board
Reuters  ·  12-24
Vor Biopharma Adds Andrew Levin and Wouter Joustra to Board
Vor Bio Appoints Ra Capital’s Andrew Levin, M.d., Ph.d., and Forbion’s Wouter Joustra to Board of Directors
THOMSON REUTERS  ·  12-24
Vor Bio Appoints Ra Capital’s Andrew Levin, M.d., Ph.d., and Forbion’s Wouter Joustra to Board of Directors
Vor Biopharma Inc. Files Initial Statement of Beneficial Ownership for Director Andrew David Levin
Reuters  ·  12-20
Vor Biopharma Inc. Files Initial Statement of Beneficial Ownership for Director Andrew David Levin
BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks
Reuters  ·  12-17
BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks
Vor Biopharma Initiated at Buy by TD Cowen
Dow Jones  ·  12-17
Vor Biopharma Initiated at Buy by TD Cowen
Vor Biopharma Shares up 1.6% After TD Cowen Initiates Coverage With Buy Rating
THOMSON REUTERS  ·  12-17
Vor Biopharma Shares up 1.6% After TD Cowen Initiates Coverage With Buy Rating
BUZZ-U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas Roadhouse
Reuters  ·  12-17
BUZZ-U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas Roadhouse
BUZZ-Vor Bio jumps after TD Cowen initiates coverage with 'buy'
Reuters  ·  12-17
BUZZ-Vor Bio jumps after TD Cowen initiates coverage with 'buy'
TD Cowen Initiates Vor Biopharma at Buy
MT Newswires Live  ·  12-17
TD Cowen Initiates Vor Biopharma at Buy
Vor Biopharma Inc : TD Cowen Initiates Coverage With Buy Rating
THOMSON REUTERS  ·  12-17
Vor Biopharma Inc : TD Cowen Initiates Coverage With Buy Rating
Vor Biopharma Launches $150 Million Private Placement; Shares Rise
MT Newswires Live  ·  12-15
Vor Biopharma Launches $150 Million Private Placement; Shares Rise
BRIEF-Vor Bio Announces $150 Million Private Placement
Reuters  ·  12-15
BRIEF-Vor Bio Announces $150 Million Private Placement
BUZZ-U.S. STOCKS ON THE MOVE-ATMC, G-III Apparel, Cognyte
Reuters  ·  12-09
BUZZ-U.S. STOCKS ON THE MOVE-ATMC, G-III Apparel, Cognyte
Vor Biopharma Shares up 13% After JP Morgan Initiates Coverage With 'Overweight'
THOMSON REUTERS  ·  12-09
Vor Biopharma Shares up 13% After JP Morgan Initiates Coverage With 'Overweight'
Vor Biopharma Cuts Stock Option Exercise Price to $8.18 for Executives
Reuters  ·  12-09
Vor Biopharma Cuts Stock Option Exercise Price to $8.18 for Executives
BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Ares Management, Vor Bio
Reuters  ·  12-09
BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Ares Management, Vor Bio
Top Premarket Gainers
MT Newswires Live  ·  12-09
Top Premarket Gainers
BUZZ-Vor Bio jumps as J.P.Morgan initiates with 'overweight' rating
Reuters  ·  12-09
BUZZ-Vor Bio jumps as J.P.Morgan initiates with 'overweight' rating
Vor Biopharma Shares Jump 67% Premarket After JP Morgan Initiates Coverage With 'Overweight'
THOMSON REUTERS  ·  12-09
Vor Biopharma Shares Jump 67% Premarket After JP Morgan Initiates Coverage With 'Overweight'
Vor Biopharma Coverage Assumed by Wedbush at Neutral
Dow Jones  ·  11-25
Vor Biopharma Coverage Assumed by Wedbush at Neutral

Introduction

Company Name.
Vor Biopharma Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Issue price:
--